Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06990737 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck
A Phase 2 study of Cutaneous Squamous Cell Carcinoma of the Head and Neck and Clinically Node-Negative (cN0), sponsored by University of California, Davis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06990737: Recruiting Phase 2 study of Cutaneous Squamous Cell Carcinoma of the Head and Neck and Clinically Node-Negative (cN0), sponsored by University of California, Davis.
NCT06990737 is a Phase 2 study of Cutaneous Squamous Cell Carcinoma of the Head and Neck and Clinically Node-Negative (cN0) that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06990737, a Phase 2 study of Cutaneous Squamous Cell Carcinoma of the Head and Neck and Clinically Node-Negative (cN0), is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 2 pragmatic study at a single site that evaluates the clinical benefit of SLNB in patients with high-risk cSCC and cN0. The primary goal is to evaluate the efficacy of SLNB based on the DFS rate at 2 years post-definitive therapy.
Conditions Studied
Interventions
- PROCEDURE Sentinel lymph node biopsy (SLNB)
- PROCEDURE Lymphadenectomy
- DRUG Adjuvant Definitive Therapy
Study Locations (1)
California
- University of California, Davis - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-06-25 |
| Est. Completion | 2032-08-01 |
| Phase | Phase 2 |
What NCT06990737 shows while recruiting
NCT06990737 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 3 conditions, with Cutaneous Squamous Cell Carcinoma of the Head and Neck appearing as the primary indexed condition, and to 3 interventions - of which Sentinel lymph node biopsy (SLNB) is the first listed.
NCT06990737 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06990737 about?
NCT06990737 is a clinical study titled "Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck". This is a phase 2 pragmatic study at a single site that evaluates the clinical benefit of SLNB in patients with high-risk cSCC and cN0. The primary goal is to evaluate the efficacy of SLNB based on the DFS rate at 2 years post-definitive therapy.
What is the current status of trial NCT06990737?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2025-06-25. Estimated completion is 2032-08-01.
What conditions does trial NCT06990737 study?
This clinical trial studies the following conditions: Cutaneous Squamous Cell Carcinoma of the Head and Neck, Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck.
What interventions are being tested in trial NCT06990737?
The interventions under investigation include: Sentinel lymph node biopsy (SLNB) (PROCEDURE), Lymphadenectomy (PROCEDURE), Adjuvant Definitive Therapy (DRUG).
Who is sponsoring clinical trial NCT06990737?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06990737 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Squamous Cell Carcinoma of the Head and Neck
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06990737's enrollment target sits among peer trials
24 1756th of 2000 higher than 218 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI